Y-mAbs Therapeutics, Inc. Made Headway
Y-mAbs Therapeutics, Inc. (YMAB:NASDAQ) shot up at $8.52, a gain of 103.3%. On Tue, Aug 05, 2025, YMAB:NASDAQ hit a New 2-Week High of $8.52. The stock appeared on our News Catalysts scanner on Tue, Aug 05, 2025 at 11:47 AM in the 'ACQUISITION' category. From Tue, Jul 22, 2025, the stock recorded 60.00% Up Days and 54.55% Green Days
About Y-mAbs Therapeutics, Inc. (YMAB:NASDAQ)
Y-mAbs Therapeutics Inc is a late-stage clinical biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. Products developed by the company include naxitamab for the treatment of pediatric patients with relapsed or refractory and radiolabeled omburtamab for the treatment of pediatric patients with central nervous system.
Top 10 Gainers:
- Ikena Oncology, Inc. (IKNA:NASDAQ), 1152.55%
- Y-mAbs Therapeutics, Inc. (YMAB:NASDAQ), 103.34%
- Visionary Holdings Inc. (GV:NASDAQ), 89.81%
- SolarMax Technology, Inc. (SMXT:NASDAQ), 78.49%
- Ameresco, Inc. (AMRC:NYSE), 48.98%
- STAAR Surgical Company (STAA:NASDAQ), 46.13%
- Xometry, Inc. (XMTR:NASDAQ), 42.98%
- Ontrak, Inc. (OTRK:NASDAQ), 40.06%
- Zepp Health Corporation (ZEPP:NYSE), 38.12%
- Arteris, Inc. (AIP:NASDAQ), 37.57%